Conduit Pharmaceuticals Inc. (CDT)vsInsmed Inc (INSM)
CDT
Conduit Pharmaceuticals Inc.
$0.49
+1.60%
HEALTHCARE · Cap: $1.78M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
CDT leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
CDT
Avoid27
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CDT
The strongest argument for CDT centers on Price/Book.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CDT
The primary concerns for CDT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CDT profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
CDT carries more volatility with a beta of 1.81 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
CDT generates stronger free cash flow (181M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Conduit Pharmaceuticals Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Conduit Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in oncology and rare diseases. Utilizing its proprietary drug delivery platform, Conduit aims to significantly enhance the efficacy and safety of existing therapies while minimizing side effects to improve patient outcomes. Backed by a seasoned management team with extensive experience in biopharmaceutical development, the company is well-positioned to generate strategic partnerships that can accelerate the growth of its promising product pipeline. With a commitment to pioneering therapeutic solutions, Conduit Pharmaceuticals is poised to become a vital contributor to advancements in healthcare.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?